

TABLE OF CONTENTS

August 25, 2008

No. 2103

BUSINESS

- 1 DSP to Place Top Priority on Lurasidone: New President Tada
 - NDA Filed for High-Dose Metformin
 - OD Tab Accounts for 48% of Total Sales of Amlodin
- 2 Eisai to Apply for 3 Anticancer Drugs by FY2012
- 3 Eisai Licenses Bendamustine from Symbio
- 3 Top Management Changes Made within 2 Months Announced by Ono
- 4 Pfizer Starts Detailing Macugen for AMD
- 4 Bayer, FUJIFILM RI Pharma Start Receiving Orders on Zevalin
- 5 Price Settlement Rates as of End of June Similar to Those Reported 2 Years Ago
- 5 Price Settlement Rate Reaches 53% as of July 31: Mediceo Paltac
- 6 Eliminating Losses due to Invoice Prices Higher than Sales Prices Is Not Easy: Mr Matsutani
- 6 Wholesalers' SGA Expense Ratio Drops to below 7% for the First Time
- 7 **BUSINESS NEWS IN BRIEF**
 - Kowa Licenses DPP-4 Inhibitor of Sanwa Kagaku
 - Alfresa Obtains First Right of Refusal from Nobelpharma
 - Daiichi Sankyo Begins TOB to Acquire Ranbaxy Shares
 - Yakult Recalls Elplat due to Contamination
 - Hiroyuki Saeki Appointed President of Hospira Japan
- 8 **Commentary**
 - 1st Qtr Business Wrap-up for Top-Four Domestic Pharmas

REGULATORY

- 10 Mr Masuzoe Reappointed Health Minister
- 10 EAD to Prepare Industry-Friendly Environment: New Director Kinoshita
- 11 Risk Assessment Shows Acceptability of Raw Materials for Basiliximab, Alteplase
- 11 *Koroshio* Opposed to Reference Price System
- 12 **REGULATORY NEWS IN BRIEF**
 - Bayer HealthCare Applies Rivaroxaban in the US
 - Nexavar Approved for HCC in China: Bayer HealthCare, Onyx
 - Apidra Approved to Treat Children and Adolescents with Diabetes in EU: sanofi-aventis
 - Astellas Receives Approvable Letter from US FDA for Vernakalant
 - Schering-Plough Receives Not-Approvable Letter from FDA for Sugammadex
 - NICE Not to Recommend Insurance Coverage of Molecular-Targeted Drugs for Renal Cancer

R&D

- 13 Long Lifecycles Prevent Quick Development of New Drugs in Japan: OPIR Report

- 14 Development of New Drugs for AMD Stimulated
- 14 **R&D NEWS IN BRIEF**
 - Bayer Acquires Preclinical Oncology Program from Nycomed
 - Alnylam, Takeda to Codevelop 4 RNAi Drugs
 - AZ to Jointly Develop Anticancer Drugs with Shizuoka Cancer Center
 - Proteus Sciences Embarks on Joint Research with Kyoto Univ. to Develop New Drugs for Brain Disease
 - Isentress Effective in Naïve HIV-Infected Patients: Merck
 - GSK, HSCI to Collaborate for Discovery
 - Sanofi-aventis Ties Up with Johns Hopkins Univ. for Severe Asthma, COPD

COMMENTARY

- 16 **Maurer's Healthcare Insight (98)**
 - The Mysteries of Japan Pharma: P. Reed Maurer

GENERIC

- 17 Market Price Surveys to Focus on Generics
- 18 **Commentary**
 - Gov't to Cut Social Security Spending by ¥220 Bil by Promoting Use of Generics

MEDICAL DEVICES

- 19 **13th ACCJ Media Lectures**
 - Healthcare Is an Industry, Not Consumption: Prof. Sakurai
 - MDCT Has Great Potential: Dr Hayashi
 - PCI Represents Great Progress in Management of IHD: Dr Nakamura

SELF-MEDICATION

- 20 Seven & i, Ain to Tie Up in Operating Dispensing Pharmacies
 - JPA Concerned about Impact of Seven & i-Ain Alliance on Its Members
 - Online Sale Should Be Allowed for Class 3 OTC Drugs Only: Mr Ishii
- 20 SSP Aims at Growth Rate 2 Points Above Industry Average: President Hatori
- 21 JODA Introduces Voluntary GL on Sale of OTC Drugs Online

MEDICAL FACILITIES & NURSING CARE

- 22 Over 40% of Patients Could Stop Remicade for Over 1 Year
- 22 Uterocervical Cancer Vaccination Cuts Medical Spending by ¥43 Billion
- 23 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Relation of Trust with Physicians Important for Treating Parkinson's Disease
 - Insurance Coverage of Gene Testing Advocated for ALL Drugs
 - IFN to Be Provided for 72 Weeks to Victims of Drug-Induced Hepatitis